Department of Health and Human Services officials have been meeting with pharmaceutical companies to seek voluntary cuts in drug prices, according to sources familiar with the meetings. Voluntary cuts in prices would allow the administration to immediately tout benefits of President Trump's recently announced drug pricing plan, rather than having to wait for any regulatory actions to be put forward and take effect. Trump said at the end of May that "in two weeks" drug companies would "announce voluntary massive drops in prices." It is not yet clear whether any drug companies have agreed to cut their prices voluntarily. (The Hill by Peter Sullivan)